Pharmacotherapy as adjunctive treatment for serious foot wounds in the patient with diabetes: a case study.
Chronic foot wounds in patients with diabetes present significant treatment challenges. A 54-year-old woman with type 2 diabetes and two wounds (one on the left great toe and the other on the left medial plantar surface) visited the clinic after the chronic wounds failed to respond to treatment such as hydrotherapy. Subsequent comprehensive care, including debridement; opening tunnels distal, proximal, and medial from the plantar wound; application of a growth factor-stimulant; and treatment with cilostazol to improve both macro- and microvascular circulation provided excellent wound healing. Amputation was avoided and the patient returned to her regular routine within 6 months. Pharmacotherapy may provide new adjunctive therapy options in the treatment of chronic foot wounds in patients with diabetes mellitus. Controlled clinical studies to ascertain the effects of this treatment are warranted.
Wound Healing Centers of Terre Haute and Linton, Ind, USA. doc@docmillers.com
Michael S
MS
Miller
D000287:Administration, Topical; D000900:Anti-Bacterial Agents / Q000627:therapeutic use; D002908:Chronic Disease; D000077407:Cilostazol; D003131:Combined Modality Therapy; D048909:Diabetes Complications; D017719:Diabetic Foot / Q000150:complications* / Q000188:drug therapy* / Q000473:pathology; D005260:Female; D006133:Growth Substances / Q000819:agonists; D006801:Humans; D008875:Middle Aged; D012039:Regional Blood Flow / Q000187:drug effects; D012720:Severity of Illness Index; D013777:Tetrazoles / Q000494:pharmacology / Q000627:therapeutic use; D016896:Treatment Outcome; D014945:Wound Healing / Q000187:drug effects*
D000900:Anti-Bacterial Agents; D006133:Growth Substances; D013777:Tetrazoles; D000077407:Cilostazol